Endocannabinoids inhibit the growth of free-living amoebae

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 3065-3067

  Dey, Rafik ^a,b   Pernin, Pierre ^a,b   Bodennec, Jacques ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 O ACYLGLYCEROL; 2 O ACYLGLYCEROL ETHER; ANANDAMIDE; ENDOCANNABINOID; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR AFFECTING AGENT; DRONABINOL;

ACANTHAMOEBA CASTELLANII; AMOEBA (LIFE CYCLE STAGE); ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HARTMANNELLA; HARTMANNELLA VERMIFORMIS; IC 50; NAEGLERIA; NONHUMAN; PRIORITY JOURNAL; WILLAERTIA MAGNA; ANIMAL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING;

AMOEBA; ANIMALS; CANNABINOID RECEPTOR MODULATORS; DRONABINOL; ENDOCANNABINOIDS;

EID: 77953786456     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01825-09     Document Type: Article

References (19)

1. Barnett, G., V. Licko, and T. Thompson. 1985. Behavioral pharmacokinetics of marijuana. Psychopharmacology (Berl.) 85:51-56.
2. Cabral, G. A., and F. Marciano-Cabral. 2004. Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. J. Neuroimmunol. 147:127-130.
3. Cabral, G. A., E. S. Raborn, L. Griffin, J. Dennis, and F. Marciano-Cabral. 2008. CB2 receptors in the brain: role in central immune function. Br. J. Pharmacol. 153:240-251.
4. De Jonckheere, J. 1977. Use of an axenic medium for differentiation between pathogenic and nonpathogenic Naegleria fowleri isolates. Appl. Environ. Microbiol. 33:751-757.
5. Dey, I., K. Keller, A. Belley, and K. Chadee. 2003. Identification and characterization of a cyclooxygenase-like enzyme from Entamoeba histolytica. Proc. Natl. Acad. Sci. U. S. A. 100:13561-13566.
6. Di Marzo, V., C. S. Breivogel, Q. Tao, D. T. Bridgen, R. K. Razdan, A. M. Zimmer, A. Zimmer, and B. R. Martin. 2000. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75:2434-2444.
7. Ellingson, J. S. 1980. Identification of N-acylethanolamine phosphoglycerides and acylphosphatidylglycerol as the phospholipids which disappear as Dictyostelium discoideum cells aggregate. Biochemistry 19:6176-6182.
8. Ellingson, J. S., and H. C. Dischinger. 1985. Concurrent disappearance of N-acylethanolamine glycerophospholipids and phagolysosomes enriched in N-acylethanolamine glycerophospholipids as Dictyostelium discoideum cells aggregate. Biochim. Biophys. Acta 812:255-260.
9. Karava, V., P. M. Zafiriou, L. Fasia, D. Anagnostopoulos, E. Boutou, C. E. Vorgias, M. Maccarrone, and A. Siafaka-Kapadai. 2005. Anandamide metabolism by Tetrahymena pyriformis in vitro. Characterization and identification of a 66 kDa fatty acid amidohydrolase. Biochimie 87:967-974.
10. Kishimoto, S., S. Oka, M. Gokoh, and T. Sugiura. 2006. Chemotaxis of human peripheral blood eosinophils to 2-arachidonoylglycerol: comparison with other eosinophil chemoattractants. Int. Arch. Allergy Immunol. 140(Suppl. 1):3-7.
11. Marciano-Cabral, F., and G. Cabral. 2003. Acanthamoeba spp. as agents of disease in humans. Clin. Microbiol. Rev. 16:273-307.
12. Marciano-Cabral, F., R. Puffenbarger, and G. A. Cabral. 2000. The increasing importance of Acanthamoeba infections. J. Eukaryot. Microbiol. 47:29-36.
13. McPartland, J. M., I. Matias, V. Di Marzo, and M. Glass. 2006. Evolutionary origins of the endocannabinoid system. Gene 370:64-74.
14. Pringle, H. L., S. G. Bradley, and L. S. Harris. 1979. Susceptibility of Naegleria fowleri to delta 9-tetrahydrocannabinol. Antimicrob. Agents Chemother. 16:674-679.
15. Salazar, M., A. Carracedo, I. J. Salanueva, S. Hernandez-Tiedra, M. Lorente, A. Egia, P. Vazquez, C. Blazquez, S. Torres, S. Garcia, J. Nowak, G. M. Fimia, M. Piacentini, F. Cecconi, P. P. Pandolfi, L. Gonzalez-Feria, J. L. Iovanna, M. Guzman, P. Boya, and G. Velasco. 2009. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest. 119:1359-1372.
16. Smith, P. B., D. R. Compton, S. P. Welch, R. K. Razdan, R. Mechoulam, and B. R. Martin. 1994. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:219-227.
17. Sugiura, T., S. Kishimoto, S. Oka, and M. Gokoh. 2006. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog. Lipid Res. 45:405-446.
18. Willoughby, K. A., S. F. Moore, B. R. Martin, and E. F. Ellis. 1997. The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther. 282:243-247.
19. Woodward, D. F., R. W. Carling, C. L. Cornell, H. G. Fliri, J. L. Martos, S. N. Pettit, Y. Liang, and J. W. Wang. 2008. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol. Ther. 120:71-80.